High-level expression of c-H-ras1 fails to fully transform rat-1 cells.
Open Access
- 1 April 1988
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 8 (4) , 1460-1468
- https://doi.org/10.1128/mcb.8.4.1460
Abstract
Rat-1 cells were transfected with plasmids encoding normal (Gly-12), nonactivated (Pro-12), and activated (Val-12 and Ile-12) p21H-ras in the presence of an amplifiable dihydrofolate reductase marker. The introduced DNA was amplified by selection in methotrexate to establish the relationship between p21H-ras expression and various hallmarks of cellular transformation. The maximum level of p21H-ras (Gly-12) consistent with cell viability was approximately 0.13% of total cell protein (approximately 60,000 molecules per cell); this is 44-fold greater than the level of the endogenous protein. The maximum tolerated level of a second nontransforming form of p21H-ras (pro-12) was about half of this. Amplification in Rat-1 cells of H-ras genes encoding the highly oncogenic Val-12 and Ile-12 forms of p21H-ras could not be achieved by methotrexate selection, providing strong evidence that synthesis of activated p21H-ras above a certain threshold (about 0.02% of total protein) in Rat-1 cells is incompatible with cell viability. Individual cell lines were isolated and their morphology, anchorage-independent growth, tumorigenicity, and response to and production of growth factors were studied. We report that cell lines expressing near-maximum tolerated levels of either the normal or pro-12 form of p21H-ras were not as transformed as cells expressing much more modest levels of the highly oncogenic (Val-12) form, suggesting that the complete elaboration of the transformed phenotype by ras depends, at least in part, on mutations that distinguish the cellular and viral proteins. We found that cells expressing elevated levels of the normal p21(H-ras) could be fully transformed by the activated (Val-12) form and that such cells continued to overexpress p21(H-ras) (Gly-12), arguing against a role for normal ras genes in suppression of the oncogenic potential of their mutationally activated counterparts.This publication has 48 references indexed in Scilit:
- ras GENESAnnual Review of Biochemistry, 1987
- Prevalence of ras gene mutations in human colorectal cancersNature, 1987
- Ras p21 proteins with high or low GTPase activity can efficiently transform NIH3T3 cellsCell, 1986
- Biological and biochemical properties of human rasH genes mutated at codon 61Cell, 1986
- Autocrine growth factors and cancerNature, 1985
- Expression of v-src and chicken c-src in rat cells demonstrates qualitative differences between pp60v-src and pp60c-srcCell, 1984
- G proteins and dual control of adenylate cyclaseCell, 1984
- Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutationsNature, 1983
- Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donorCell, 1978
- Suppression of Malignancy by Cell FusionNature, 1969